ProCE Banner Activity

Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers

Conference Coverage
Podcast Episodes

In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, discuss key data for gynecologic cancers presented at the 2023 SGO Annual Meeting, including practice changing data for endometrial cancers, and for novel combinations in ovarian cancer, and studies exploring sequencing immunotherapy and chemoradiation in cervical cancer.

Released: May 04, 2023

Share

Faculty

Linda R. Duska

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

David Scott Miller

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new data in cervical, endometrial, and ovarian cancers to clinical practice to expand treatment options and improve outcomes for patients with gynecologic malignancies

  • Assess predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility

  • Plan individualized treatment strategies, incorporating novel therapies and combination strategies as appropriate, for patients with cervical, endometrial, and ovarian cancers

  • Provide education and support throughout all stages of diagnosis and treatment to populations of patients with gynecologic cancers who are at increased risk for poor prognosis

Disclosure

Primary Author

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Linda Duska, MD, MPH: researcher (paid to institution): Aduro Biotech Inc, ARCH Oncology, CE3 Inc, Clinipace Inc, Corcept Therapeutics, Eisia, GlaxoSmithKline, Harpoon Therapeutics, K-Group Beta, Leap Therapeutics, Lycera, Ludwig Institute for Cancer Research, Merck Sharp and Dohme, NRG, OncoQuest, Pfizer, PharmaMar, Plexxikon, Psi Pharma Support America, Seattle Genetics, Syndax.

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

David Scott Miller, MD, FACOG, FACS: consultant/advisor/speaker: Agenus, AstraZeneca, Asymmetric, Boston Biomedical Research Institute, Eisai, Eisai Europe Limited, EMD Serono, GlaxoSmithKline, Immunogen, Incyte, iTeos Belgium SA, Karyopharm, Merck Sharp & Dohme, Myriad, Novartis, Novocure, Seagen, Tarveda Therapeutics; researcher (paid to institution): Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akesobio, Aprea AB, AstraZeneca, Immunogen, Incyte, Janssen, Karyopharm, Mateon, Merck Sharp & Dohme, Millenium, NVision, Novartis, Pfizer, Regeneron, Syros, Tesaro, Tracon, US Biotest, Xenetic; researcher: EMD Serono Research & Development, Leap.